COMPANY PROFILE

Giiant Pharma

Designs gut-restricted, tissue-specific, small molecule, drug therapeutics with various biological targets in gastroenterology

Montreal, CanadaFounded 2014Biotech & Life Sciences

Valuation $50–100M Last recorded · 2021

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Giiant Pharma

Giiant Pharma Inc. specializes in developing gut-restricted, small molecule, tissue-specific drug therapeutics aimed at treating inflammatory bowel diseases (IBD). The company focuses on precision delivery to ensure that the drugs act locally within the gut, thereby minimizing systemic exposure and enhancing patient safety. This approach aims to improve the overall care and treatment outcomes for IBD patients. Giiant Pharma operates within the pharmaceutical industry, targeting healthcare providers and patients suffering from IBD. The business model revolves around the research, development, and commercialization of these specialized therapeutics. Revenue is generated through the sale of these drugs, as well as potential partnerships and licensing agreements with other pharmaceutical companies. The company recently secured $11 million in Seed financing to advance its Precision Delivery technology platform, underscoring its commitment to innovation and effective treatment solutions.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Montreal, Canada
Employees: 4
Open positions: None listed
Dealroom signal: 81.2/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn X

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

4 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
GRANTOther financing	Dec 2023	$0	—	Undisclosed	↗
GRANT✓Other financing	Jan 2023	$500K	—	Undisclosed	↗

Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Giiant Pharma website traffic

Latest recorded traffic for Giiant Pharma is 320 monthly website visits, down 78.7% over the last three months. Giiant Pharma's team grew 0% over the past year.

Latest monthly visits320 3-month web change-78.7% 1-year team growth0%

Monthly website visitsJan 2023–Jun 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
ENEnvoyaPolymer-Based Nanoparticles for Targeted delivery	Boston, United States	Operational	10	$2M	$8M
TGTongshu GeneA high-tech enterprise that focuses on scientific and technological innovation and focuses on precise molecular diagnosis of tumors	China	Operational
MIMicroMGxThe MGx platform technology, discovers new chemistry by harnessing the power of microbes	Chicago, United States	Operational
BPBio PaletteBio Palette aims to become a world-leading company in the field of microbiome therapeutics by using bacteria optimized by genome editing to modify and control microbiomes	Kobe, Japan	Operational
BIBiospinA biotechnology company developing solutions to protect people from pathogens	Singapore, Singapore	Operational
AVAvantGuardAvantGuard (formerly Halomine) manufactures and supplies high-performance and human-friendly antimicrobial coating materials and technology	Ithaca, United States	Operational
ACActXFocused on making patient genomic information that are useful in everyday medical practice	Seattle, United States	Operational
BIBillionToOneThe only genetic testing platform that accurately and efficiently detects and measures disease at the molecular level	Menlo Park, United States	Operational